PolyPid Ltd. Ordinary Shares
PYPDStock
$5.19+57.82%52W
Market Cap$99.42M
P/E—
Div yield—
Beta1.41
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)8.39%
Price vs S&P 500 (4W)15.08%
VGM Score80.84
Market Capitalization$99.42M
Earnings Surprise History
Q1 26-0.35est. -0.44
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.10
4.10
4.10
4.10
Industry Peers — Surgical & Medical Instruments(141)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
PYPDPolyPid Ltd. Ordinary Shares | — | — | A | $5.19 |
| SYKStryker Corporation | C | C | D | $331.20 |
| MMM3M Company | C | F | B | $161.77 |
| BSXBoston Scientific Corp. | C | B | F | $44.62 |
| MDLNMedline Inc. Class A common stock | C | D | D | $41.11 |
| BDXBecton, Dickinson and Co. | B | C | B | $159.93 |
| DXCMDexCom, Inc. | C | B | C | $77.98 |
| RMDResMed Inc. | C | B | D | $202.76 |
| WSTWest Pharmaceutical Services, Inc. | D | C | A | $362.44 |
| SOLVSolventum Corporation | C | D | B | $81.70 |
| PENPenumbra, Inc. | F | C | B | $319.60 |
About
PolyPid Ltd is a clinical-stage biopharmaceutical company developing therapies based on PLEX, its proprietary drug delivery technology that enables targeted, localized drug release over extended periods. The company's lead candidate, D-PLEX100, is being developed to prevent surgical site infections, while OncoPLEX represents a potential intra-tumoral cancer treatment platform.